On the other hand, GHR inhibits cell apoptosis of the beta-cells induced by lipotoxicity, transforming GHR agonists into a promising therapeutic path to preserve and improve the function of the remaining beta-cells in the early stages of both T1DM and T2DM. The gene discussed is GHR; the disease is type 2 diabetes mellitus.